Common single nucleotide polymorphisms at the NPC1L1 gene locus significantly predict cardiovascular risk in coronary patients

Atherosclerosis

Volumn 242, Issue 1, 2015, Pages 340-345

  Muendlein, Axel ^a,b   Leiherer, Andreas ^a,b,d   Saely, Christoph H ^a,b,c   Rein, Philipp ^a,c   Zanolin, Daniela ^a,b   Kinz, Elena ^a,b   Brandtner, Eva Maria ^a   Fraunberger, Peter ^d   Drexel, Heinz ^a,b,c,e  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^c ACADEMIC TEACHING HOSPITAL FELDKIRCH   (Austria)

^d Medical Central Laboratory   (Austria)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular risk; Cholesterol; Coronary artery disease; NPC1L1; Single nucleotide polymorphisms

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEMBRANE PROTEIN; NIEMANN PICK C1 LIKE 1 PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; NPC1L1 PROTEIN, HUMAN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRIACYLGLYCEROL BLOOD LEVEL; AUSTRIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EPIDEMIOLOGY; ETHNOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PHENOTYPE; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR;

AGED; AUSTRIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84939559330     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.07.011     Document Type: Article

References (34)

1. Altmann S.W., Davis H.R., Zhu L.J., Yao X., Hoos L.M., Tetzloff G., Iyer S.P., Maguire M., Golovko A., Zeng M., Wang L., Murgolo N., Graziano M.P. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303(5661):1201-1204.
2. Davies J.P., Scott C., Oishi K., Liapis A., Ioannou Y.A. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 2005, 280(13):12710-12720.
3. Davies J.P., Levy B., Ioannou Y.A. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 2000, 65(2):137-145.
4. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343(6257):425-430.
5. Garcia-Calvo M., Lisnock J., Bull H.G., Hawes B.E., Burnett D.A., Braun M.P., Crona J.H., Davis H.R., Dean D.C., Detmers P.A., Graziano M.P., Hughes M., Macintyre D.E., Ogawa A., O'neill K.A., Iyer S.P., Shevell D.E., Smith M.M., Tang Y.S., Makarewicz A.M., Ujjainwalla F., Altmann S.W., Chapman K.T., Thornberry N.A. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U. S. A. 2005, 102(23):8132-8137.
6. Ezzet F., Wexler D., Statkevich P., Kosoglou T., Patrick J., Lipka L., Mellars L., Veltri E., Batra V. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J. Clin. Pharmacol. 2001, 41(9):943-949.
7. Phan B.A., Dayspring T.D., Toth P.P. Ezetimibe therapy: mechanism of action and clinical update. Vasc. Health Risk Manag. 2012, 8:415-427.
8. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., Visseren F.L., Sijbrands E.J., Trip M.D., Stein E.A., Gaudet D., Duivenvoorden R., Veltri E.P., Marais A.D., de Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 2008, 358(14):1431-1443.
9. Blazing M.A., Giugliano R.P., Cannon C.P., Musliner T.A., Tershakovec A.M., White J.A., Reist C., McCagg A., Braunwald E., Califf R.M. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am. Heart J. 2014, 168(2):205-212.
10. Stitziel N.O., Won H.H., Morrison A.C., Peloso G.M., Do R., Lange L.A., Fontanillas P., Gupta N., Duga S., Goel A., Farrall M., Saleheen D., Ferrario P., Konig I., Asselta R., Merlini P.A., Marziliano N., Notarangelo M.F., Schick U., Auer P., Assimes T.L., Reilly M., Wilensky R., Rader D.J., Hovingh G.K., Meitinger T., Kessler T., Kastrati A., Laugwitz K.L., Siscovick D., Rotter J.I., Hazen S.L., Tracy R., Cresci S., Spertus J., Jackson R., Schwartz S.M., Natarajan P., Crosby J., Muzny D., Ballantyne C., Rich S.S., O'Donnell C.J., Abecasis G., Sunyaev S., Nickerson D.A., Buring J.E., Ridker P.M., Chasman D.I., Austin E., Ye Z., Kullo I.J., Weeke P.E., Shaffer C.M., Bastarache L.A., Denny J.C., Roden D.M., Palmer C., Deloukas P., Lin D.Y., Tang Z.Z., Erdmann J., Schunkert H., Danesh J., Marrugat J., Elosua R., Ardissino D., McPherson R., Watkins H., Reiner A.P., Wilson J.G., Altshuler D., Gibbs R.A., Lander E.S., Boerwinkle E., Gabriel S., Kathiresan S. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N. Engl. J. Med. 2014, 371(22):2072-2082.
11. Polisecki E., Peter I., Simon J.S., Hegele R.A., Robertson M., Ford I., Shepherd J., Packard C., Jukema J.W., de Craen A.J., Westendorp R.G., Buckley B.M., Schaefer E.J. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J. Lipid Res. 2010, 51(5):1201-1207.
12. Lauridsen B.K., Stender S., Frikke-Schmidt R., Nordestgaard B.G., Tybjaerg-Hansen A. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur. Heart J. 2015, 36(25):1601-1608.
13. Mirshahi U.L., Carey D.J. Mutations in NPC1L1 and coronary heart disease. N. Engl. J. Med. 2015, 372(9):881.
14. Silbernagel G., Baumgartner I., Marz W. Mutations in NPC1L1 and coronary heart disease. N. Engl. J. Med. 2015, 372(9):882.
15. Villa F. Mutations in NPC1L1 and coronary heart disease. N. Engl. J. Med. 2015, 372(9):882-883.
16. Weingartner O., Lutjohann D., Patel S.B. Mutations in NPC1L1 and coronary heart disease. N. Engl. J. Med. 2015, 372(9):881-882.
17. Gao W.Q., Feng Q.Z., Li Y.F., Li Y.X., Huang Y., Chen Y.M., Yang B., Lu C.Y. Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound. BMC Cardiovasc. Disord. 2014, 14:60.
18. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M.J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., Filardi P.P., Riccardi G., Storey R.F., Wood D. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011, 32(14):1769-1818.
19. Drexel H., Amann F.W., Beran J., Rentsch K., Candinas R., Muntwyler J., Luethy A., Gasser T., Follath F. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation 1994, 90(5):2230-2235.
20. Voight B.F., Kang H.M., Ding J., Palmer C.D., Sidore C., Chines P.S., Burtt N.P., Fuchsberger C., Li Y., Erdmann J., Frayling T.M., Heid I.M., Jackson A.U., Johnson T., Kilpelainen T.O., Lindgren C.M., Morris A.P., Prokopenko I., Randall J.C., Saxena R., Soranzo N., Speliotes E.K., Teslovich T.M., Wheeler E., Maguire J., Parkin M., Potter S., Rayner N.W., Robertson N., Stirrups K., Winckler W., Sanna S., Mulas A., Nagaraja R., Cucca F., Barroso I., Deloukas P., Loos R.J., Kathiresan S., Munroe P.B., Newton-Cheh C., Pfeufer A., Samani N.J., Schunkert H., Hirschhorn J.N., Altshuler D., McCarthy M.I., Abecasis G.R., Boehnke M. The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet. 2012, 8(8):e1002793.
21. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81(3):559-575.
22. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Lochner A., Faggart M., Liu-Cordero S.N., Rotimi C., Adeyemo A., Cooper R., Ward R., Lander E.S., Daly M.J., Altshuler D. The structure of haplotype blocks in the human genome. Science 2002, 296(5576):2225-2229.
23. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
24. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68(4):978-989.
25. Stephens M., Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 2003, 73(5):1162-1169.
26. Desmet F.O., Hamroun D., Lalande M., Collod-Beroud G., Claustres M., Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2009, 37(9):e67.
27. Betters J.L., Yu L. NPC1L1 and cholesterol transport. FEBS Lett. 2010, 584(13):2740-2747.
28. Ference B.A., Yoo W., Alesh I., Mahajan N., Mirowska K.K., Mewada A., Kahn J., Afonso L., Williams K.A., Flack J.M. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J. Am. Coll. Cardiol. 2012, 60(25):2631-2639.
29. Ference B.A., Majeed F., Penumetcha R., Flack J.M., Brook R.D. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial mendelian randomization study. J. Am. Coll. Cardiol. 2015, 65(15):1552-1561.
30. Kathiresan S. Developing medicines that mimic the natural successes of the human genome: lessons from NPC1L1, HMGCR, PCSK9, APOC3, and CETP. J. Am. Coll. Cardiol. 2015, 65(15):1562-1566.
31. Labonte E.D., Camarota L.M., Rojas J.C., Jandacek R.J., Gilham D.E., Davies J.P., Ioannou Y.A., Tso P., Hui D.Y., Howles P.N. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295(4):G776-G783.
32. Hiramitsu S., Ishiguro Y., Matsuyama H., Yamada K., Kato K., Noba M., Uemura A., Yoshida S., Matsubara Y., Kani A., Hasegawa K., Hishida H., Ozaki Y. The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J. Atheroscler. Thromb. 2010, 17(1):106-114.
33. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N. Engl. J. Med. 1992, 326(5):310-318.
34. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N. Engl. J. Med. 1992, 326(4):242-250.